Home / Intelligence / Case Studies / Strategic Recommendations About Potential Actions to Shape Bone Health Policy
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope: 
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the most relevant health policy shaping stakeholders, their actions, and consequent impact; leverage key learnings from each analogue disease area to inform bone health policy recommendations.
Deliverables
- Analogue selection and methodology
- High level executive summary explaining overall trends
- Analogue assessments for five disease areas of interest
- Recommendations for exploring partnerships in developing bone health policy
Project Outcomes & Impact
The client was able to understand the strategic actions they could take in order to shape bone health policy across several markets and define the success factors that drive stakeholder engagement in policy-shaping activities. The client was also able to develop compelling case studies in order to gather cross-functional buy-in.
Related Intelligence
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More